AEterna Zentaris Inc. (AEZS) Receives Consensus Rating of “Strong Buy” from Brokerages

Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a twelve-month consensus target price of $5.50 for the company and are anticipating that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also given AEterna Zentaris an industry rank of 82 out of 256 based on the ratings given to its competitors.

Several analysts recently weighed in on AEZS shares. ValuEngine upgraded shares of AEterna Zentaris from a “hold” rating to a “buy” rating in a report on Wednesday, May 1st. Zacks Investment Research upgraded shares of AEterna Zentaris from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a report on Monday, March 18th.

Shares of NASDAQ AEZS traded down $0.38 during midday trading on Thursday, reaching $2.46. 295,291 shares of the stock were exchanged, compared to its average volume of 279,582. The company has a market capitalization of $46.20 million, a P/E ratio of 9.84 and a beta of 1.34. AEterna Zentaris has a twelve month low of $1.29 and a twelve month high of $5.57.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.04 by ($0.18). The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $4.20 million. AEterna Zentaris had a negative return on equity of 328.95% and a negative net margin of 666.76%. As a group, equities research analysts forecast that AEterna Zentaris will post 1.71 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of AEZS. Acadian Asset Management LLC grew its stake in shares of AEterna Zentaris by 27.2% in the fourth quarter. Acadian Asset Management LLC now owns 45,049 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 9,640 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of AEterna Zentaris in the fourth quarter worth $30,000. Virtu Financial LLC acquired a new position in shares of AEterna Zentaris in the first quarter worth $179,000. O Shaughnessy Asset Management LLC acquired a new position in shares of AEterna Zentaris in the fourth quarter worth $66,000. Finally, Renaissance Technologies LLC grew its stake in shares of AEterna Zentaris by 232.8% in the first quarter. Renaissance Technologies LLC now owns 110,078 shares of the biopharmaceutical company’s stock worth $512,000 after acquiring an additional 77,000 shares in the last quarter. Hedge funds and other institutional investors own 13.67% of the company’s stock.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Further Reading: How to use beta for portfolio diversification

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.